data reads well...
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Purva Jain, John H. Alexander, P. **riel Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise M. D'Andrea, Lawrence I. Deckelbaum, Bela Merkely, Maciej Zarebinski, Ton Oude Ophuis and Robert A. Harrington
Abstract
Background—Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction.
Methods—The AEGIS-I trial (Apo-I Event Reducing in Ischemic Syndromes I) was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Patients with myocardial infarction were stratified by renal function and randomized 1:1:1 to CSL112 (2 g apoA-I per dose) and high-dose CSL112 (6 g apoA-I per dose), or placebo for 4 consecutive weekly infusions. Coprimary safety end points were occurrence of either a hepatic safety event (an increase in alanine transaminase >3 times the upper limit of normal or an increase in total bilirubin >2 times the upper limit of normal) or a renal safety event (an increase in serum creatinine >1.5 times the baseline value or a new requirement for renal replacement therapy).
Results—A total of 1258 patients were randomized, and 91.2% received all 4 infusions. The difference in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was within the protocol-defined noninferiority margin of 4%. Similarly, the difference in incidence rates for an increase in serum creatinine or a new requirement for renal replacement therapy was within the protocol-defined noninferiority margin of 5%. CSL112 was associated with increases in apoA-I and ex vivo cholesterol efflux similar to that achieved in patients with stable coronary artery disease. In regard to the secondary efficacy end point, the risk for the composite of major adverse cardiovascular events among the groups was similar.
Conclusions—Among patients with acute myocardial infarction, 4 weekly infusions of CSL112 are feasible, well tolerated, and not associated with any significant alterations in liver or kidney function or other safety concern. The ability of CSL112 to acutely enhance cholesterol efflux was confirmed. The potential benefit of CSL112 to reduce major adverse cardiovascular events needs to be assessed in an adequately powered phase 3 trial.
- Forums
- ASX - By Stock
- CSL
- Ann: Positive Results from CSL112 Phase 2b Trial
Ann: Positive Results from CSL112 Phase 2b Trial, page-3
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$300.26 |
Change
-1.400(0.46%) |
Mkt cap ! $145.3B |
Open | High | Low | Value | Volume |
$303.31 | $303.47 | $299.56 | $148.6M | 498.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 276 | $300.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$300.34 | 1250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 250 | 300.000 |
1 | 99 | 299.950 |
1 | 5 | 299.650 |
1 | 6 | 299.500 |
2 | 32 | 299.100 |
Price($) | Vol. | No. |
---|---|---|
300.650 | 59 | 1 |
301.160 | 55 | 1 |
301.660 | 35 | 1 |
301.890 | 19 | 1 |
302.000 | 53 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online